You are here
Oncology - viral therapy for cancer
Latvia has been accumulating experience in oncological disease research and treatment for over seventy years, which ensures absolutely superb levels of quality in the education of specialists in this area. Thanks to their qualifications, as well as the modern equipment they have available for use, the methods used, and high level of quality inherent in their examinations, Latvian oncology specialists are some of the best in Europe.
Latvia offers a unique method of treatment for oncological diseases, utilising viral therapy based on RIGVIR, which is the only living, natural virus that contains substances that possess oncotropic and oncolytic properties as well as the ability to find and destroy malignant cells. It has passed all phases of clinical trials, and is registered in Latvia (Reg. No. 04-0229), and is also available in Latvian pharmacies.
Viral therapy with RIGVIR is distinguished by a comparatively high therapeutic effect, insignificant adverse reactions, the ability to activate the body’s immune system, and affordable treatment costs.
Viral therapy can be combined with other treatment methods. RIGVIR’s ability to treat melanoma, which is considered to be one of the most aggressive types of cancer, should specifically be noted.
The use of viruses in the treatment of malignant tumours is a subject that is being intensively studied all over the world. Today it is arguable that scientists around the world have become more and more inclined to use viral therapy as one of main therapies in the treatment of cancer. Thanks to the great scientific achievement that has been termed RIGVIR, Latvia has become a world leader in the area of viral therapy.
Viral therapy is available in all Latvian public and private health care facilities that deal with the treatment of oncological diseases. Latvian scientists and doctors have established the Latvian Virotherapy Centre which specialises in the practical use of viral therapy and in training doctors, and it works in cooperation with the Latvian Association of Virotherapy.